BMJ Open Conjoint analysis to understand preferences of patients with multiple sclerosis for disease-modifying therapy attributes in Spain: a cross-sectional observational study

Rafael Arroyo,¹ Angel P Sempere,² Elena Ruiz-Beato,³ Daniel Prefasi,⁴ Agata Carreño,⁵ Montse Roset,⁵ Jorge Maurino⁴

To cite: Arroyo R, Sempere AP, Ruiz-Beato E, *et al.* Conjoint analysis to understand preferences of patients with multiple sclerosis for disease-modifying therapy attributes in Spain: a cross-sectional observational study. *BMJ Open* 2017;**7**:e014433. doi:10.1136/bmjopen-2016-014433

► Prepublication history for this paper is available online. To view these files please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2016-014433>).

Received 27 September 2016

Revised 20 December 2016

Accepted 16 January 2017

CrossMark

For numbered affiliations see end of article.

Correspondence to

Dr Jorge Maurino;
jorge.maurino@roche.com

ABSTRACT

Objective: To assess patients' preferences for a range of disease-modifying therapy (DMT) attributes in multiple sclerosis (MS).

Design: A cross-sectional observational study.

Setting: The data reported were from 17 MS units throughout Spain.

Participants: Adult patients with relapsing-remitting MS.

Main outcome: A conjoint analysis was applied to assess preferences. A total of 221 patients completed a survey with 10 hypothetical DMT profiles developed using an orthogonal design and rating preferences from 1 (most acceptable) to 10 (least acceptable). Medication attributes included preventing relapse, preventing disease progression, side effect risk, route and frequency of administration.

Results: Patients placed the greatest relative importance on the side effect risk domain (32.9%), followed by route of administration (26.1%), frequency of administration (22.7%), prevention of disease progression (10.0%) and prevention of relapse (8.3%). These results were independent of the Expanded Disability Status Scale score. The importance assigned to side effect risk was highest for patients with a recent diagnosis. Patients who had previously received more than one DMT gave a higher importance to relapse rate reduction than patients receiving their first DMT.

Conclusions: Patient DMT preferences were mainly driven by risk minimisation, route of administration and treatment schedule. The risk-benefit spectrum of available DMT for MS is becoming increasingly complicated. Understanding which treatment characteristics are meaningful to patients may help to tailor information for them and facilitate shared decision-making in clinical practice.

INTRODUCTION

Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central

Strengths and limitations of this study

- Little is known about the patients' preferences for different attributes of multiple sclerosis (MS) drug therapy.
- This study included a sample of 221 patients with relapsing-remitting MS managed in 17 different MS units at the national level, which allows results to be generalised to community practice. A comprehensive battery of the most important disease-modifying therapy attributes, including efficacy, tolerability, safety and convenience (route and frequency of administration), was analysed.
- The inclusion of a high percentage of patients with short disease duration is the main limitation of the study.

nervous system with genetic and environmental factors involved.¹ Relapsing-remitting MS (RRMS) is the most common clinical form of MS. The first-generation of disease-modifying therapies (DMTs), β -interferons and glatiramer acetate, reduced the risk of relapses, were generally well tolerated and safe.² Recently, an increasing number of new drugs have shown encouraging results for the management of RRMS due to higher efficacies compared with first-line DMTs. Consequently, major changes in the therapeutic management of RRMS are expected in coming years, which can impact on the natural progression of the disease. However, despite improved efficacy, these new agents have been associated with increased risk of serious adverse effects, thus altering the risk-benefit balance.²⁻⁴ The choice of new drugs should take into account aspects other than efficacy, including mechanisms of action, duration of effect, potential safety problems,

convenience and patient preferences.⁵ In this context, therapeutic decisions are becoming increasingly complex.

In recent decades, there has been a big change in the physician–patient relationship. Patients and health authorities are increasingly demanding a more active role in decision-making processes related to medical care. This approach requires the patient to assess benefits and risks. Thus, in the management of MS, it is important to involve patients in the decision-making process regarding treatment initiation or switching due to the risk–benefit spectrum of the different DMTs available (partially effective and with significant side effect risk).^{6–8}

In the real-world setting, patients evaluate a range of features to make decisions. The analysis of preferences can be used to further improve the knowledge of which treatment attributes are considered the most valuable by patients.⁹ There are different approaches for assessing patient preferences: methods using rating or choice designs to quantify preferences for various attributes of an intervention (conjoint analysis or stated-choice methods) or methods using direct elicitation of monetary values of an intervention (including contingent valuation or willingness-to-pay and willingness-to-accept methods).¹⁰ Conjoint analysis is a multivariate technique in that the implicit values for an attribute of an intervention are derived from some overall score for a profile consisting of two or more attributes. Conjoint analysis has been conducted successfully to assess preferences for a diverse range of health interventions.¹⁰

The objective of this study was to assess the relative importance of a number of hypothetical DMT attributes for patients with RRMS.

METHODS

A multicentre observational cross-sectional study in adult patients with RRMS was conducted in 17 MS units throughout Spain (the EMPOWER study). The study was conducted between January and March 2016.

Patients were enrolled into the study who were aged 18 years or older with a diagnosis of RRMS (2010 McDonald criteria¹¹), an Expanded Disability Status Scale¹² (EDSS) score from 1 to 6, and receiving a DMT for at least the past 3 months prior to inclusion. Written informed consent was obtained from all participants. Investigators included the first 12 consecutive patients who met the inclusion criteria for study participation. Competitive recruitment was established among centres. Study patients were treated by participating neurologists following current clinical practice and according to their judgement.

Conjoint analysis required the definition of hypothetical treatment options in terms of attributes (characteristics) and a subset of levels for each attribute. The DMT attributes and levels were developed through a review of current clinical trial literature and advanced clinical

expertise.^{13 14} A total of five attributes and two to four levels per attribute were defined to take into account the most important characteristics of all available DMTs: preventing relapse, preventing disease progression, side effect risk, route and frequency of administration (table 1). An orthogonal design was used to construct 10 cards containing unique combinations of all five attributes (table 2). Patients were asked to assess the level of each attribute combined to evaluate overall preference for each card relative to the other by first placing each card on a number line from 1 to 10 (1 being the best and 10 the worst possible selection).

Sociodemographic and clinical characteristics of the sample and patient-reported questionnaires were also collected. The EDSS was used to measure disability. Health-related quality of life (HRQoL) was assessed using the EuroQol five dimensions questionnaire (EQ-5D).¹⁵ The nine-item Shared Decision-Making Questionnaire (SDM-Q-9)¹⁶ is a patient-report tool for measuring patients' perceptions of how clinician performance fits the shared decision-making process. Total score ranges from 0 to 45 (the lowest to the highest extent of shared decision-making). Cognitive functioning was assessed using the Medical Outcomes Study Cognitive Functioning Scale (MOS Cog-R scale),¹⁷ a six-item self-report instrument that measures a range of day-to-day problems in several dimensions of cognitive functioning, including memory, attention/concentration and reasoning over the previous 4 weeks. Total scores range from 0 to 100 points, with higher scores indicating greater cognitive performance.

Table 1 DMT attributes and levels

Attributes	Levels	Description
Preventing relapse	2	Presenting a relapse every 2 years Presenting a relapse every 5 years
Preventing disease progression	2	Preventing the disease from getting worse/progressing for 2 years Preventing the disease from getting worse/progressing for 5 years
Side effect risk	2	Rare but severe, life-threatening side effects (including PML) Frequent but mild/moderate side effects
Route of administration	3	Oral Subcutaneous–intramuscular Intravenous
Frequency of administration	4	Daily Every 2 days—weekly Monthly Twice per year

PML, Progressive multifocal leukoencephalopathy.

Table 2 Set of cards

Card	Preventing relapse	Preventing disease progression	Side effect risk	Route of administration	Frequency of administration
A	Presenting a relapse every 2 years	Preventing the disease from getting worse/ progressing for 5 years	Rare but severe life-threatening side effects (including PML)	Oral	Daily
B	Presenting a relapse every 2 years	Preventing the disease from getting worse/ progressing for 2 years	Frequent but mild/moderate side effects	Subcutaneous–intramuscular	Daily
C	Presenting a relapse every 5 years	Preventing the disease from getting worse/ progressing for 5 years	Rare but severe life-threatening side effects (including PML)	Intravenous	Daily
D	Presenting a relapse every 5 years	Preventing the disease from getting worse/ progressing for 2 years	Frequent but mild/moderate side effects	Oral	Every 2 days—weekly
E	Presenting a relapse every 2 years	Preventing the disease from getting worse/ progressing for 5 years	Rare but severe life-threatening side effects (including PML)	Subcutaneous–intramuscular	Every 2 days—weekly
F	Presenting a relapse every 2 years	Preventing the disease from getting worse/ progressing for 5 years	Rare but severe life-threatening side effects (including PML)	Oral	Monthly
G	Presenting a relapse every 5 years	Preventing the disease from getting worse/ progressing for 2 years	Rare but severe life-threatening side effects (including PML)	Subcutaneous–intramuscular	Monthly
H	Presenting a relapse every 2 years	Preventing the disease from getting worse/ progressing for 5 years	Frequent but mild/moderate side effects	Intravenous	Monthly
I	Presenting a relapse every 5 years	Preventing the disease from getting worse/ progressing for 5 years	Frequent but mild/moderate side effects	Subcutaneous–intramuscular	Twice per year
J	Presenting a relapse every 2 years	Preventing the disease from getting worse/ progressing for 2 years	Rare but severe life-threatening side effects (including PML)	Intravenous	Twice per year

Statistical analysis

Relative preferences were derived from rankings assigned by study patients to the 10 hypothetical scenarios, obtaining values ranging from 0 to 10. Rankings had a hierarchical order that showed which cards were more or less preferred on an arbitrary scale. Patient preferences for hypothetical treatment were collected for the overall sample of valid patients and for stratified subgroups according to the EDSS score (1–3.0 and 3.5–6.0) with the aim to check that the preferences remain stable for different levels of disability. An ordinary least squares (OLS) regression model was used to estimate parameters, given that preferences were obtained in terms of ranges.

The model estimated by the OLS method, depending on the attributes and levels, is as follows:

$$y_t = \alpha + \sum \beta_{ij} x_{ij} + e$$

Where:

y_t is the utility for a card t ;

α is the constant or intercept term;

β_{ij} is the utility or part-worth associated with the i -th attribute in the j -th level;

$x_{ij}^1=1$ when the j -th level of the i -th attribute is present in the card t ;

$x_{ij}^0=0$ when the j -th level of the i -th attribute is not present in the card t ;

e is the error term.

The DMT preference card was the dependent variable and attributes used in the definition of the cards were independent variables. Relative (overall) and individual (at patient level) importance assigned to each attribute was derived by dividing the importance of a factor (maximum difference in utility values assigned to the levels) by the sum of all individual importance scores. The relationship between sociodemographic and clinical characteristics of patients, degree of patient disability, HRQoL, cognitive function and role in shared decision-making, and preference for treatment attributes were analysed using bivariate tests. A sensitivity analysis was performed which excluded those patients with inverse preferences (or investments) in efficacy and safety attributes.

Individual importance of each attribute (or level) for obtaining information about factors related to the importance assigned to different attributes was explored according to sociodemographic and clinical variables using bivariate tests.

RESULTS

A total of 221 patients were included in the study. The mean age was 42.1 ± 9.9 years, and 68.3% were female. The mean EDSS score was 2.7 ± 1.5 . Patients presented mean SDM-Q-9 and MOS Cog-R total scores of 38.7 ± 8.5 and 41.5 ± 11.1 , respectively. The most common current DMTs were first-line injectable therapies (43.9% of patients), followed by fingolimod (19.0%), dimethyl fumarate (15.4%) and natalizumab (12.2%). The main sociodemographic and clinical characteristics of the sample are presented in table 3.

Table 4 describes estimated utilities reported by patients for attributes and levels assessed in hypothetical treatment scenarios. Patients had a higher preference for treatments with better efficacy (presenting a relapse every 5 years and/or preventing the disease from getting worse/progressing for 5 years), lower side effect risk (frequent but mild/moderate side effects), oral administration and lower frequency of administration (twice a year). Pearson's R and Kendall's τ coefficients, which provide measures of the correlation between observed and estimated preferences to assess the model's goodness of fit, showed high correlation coefficients (0.998 and 0.956, respectively). Importance assigned to the different attributes show some differences according to the method used (average or relative importance). Considering the relative importance, the most important attribute for a DMT was tolerability/safety (32.9%), followed by route of administration (26.1%) and frequency of administration (22.7%). Average importance, obtained at the patient level, was slightly different with schedule of administration being the most important attribute (26.9%), followed by side effects (26.8%) and route of administration (25.1%). Estimated utilities reported by patients for attributes and levels were

consistent in groups of patients stratified according to the EDSS score (1.0–3.0 and 3.5–6.0 strata; figure 1).

The sensitivity analysis performed, excluding those patients who showed individual reversed utilities in efficacy and safety attributes, put greater value in presenting a relapse in 5 years (0.773 vs 0.367) and preventing the disease from getting worse or progressing for 5 years (0.764 vs 0.445), but a minor preference for treatments administered twice per year (0.727 vs 1.137).

Table 5 describes sociodemographic and clinical variables related to individual importance assigned to each DMT attribute. Patients having previously received more than one DMT gave a higher importance to relapse rate reduction than patients receiving their first DMT. The importance assigned to side effect risk was highest for those patients with a recent diagnosis of <1 year.

DISCUSSION

Treatment decisions in MS are becoming difficult after the introduction of several new DMTs with more complicated spectrums of risks and benefits.¹⁸ Involving patients with MS in the decision-making process is key to selecting the treatment that best suits the patient's profile and preferences. In our study, patients placed the greatest importance on the side effect risk domain with 32.9% relative importance, followed by route of administration (26.1%), frequency of administration (22.7%), prevention of disease progression (10.0%) and prevention of relapse (8.3%).

Several studies DMT preferences of patients with MS were recently published.^{12 13 19–28} Such studies evaluated different spectrums of drug attributes. In a sample of 651 patients from the USA, a survey using five efficacy and safety drug attributes found that a delay in years to

Table 3 Main characteristics of the sample

	EDSS 1.0–3.0 (n=143)	EDSS 3.5–6.0 (n=78)	Total (n=221)	p Value
Age, mean (SD)	40.0 (9.8)	46.0 (8.9)	42.1 (9.9)	<0.001
Gender, female, n (%)	99 (69.2%)	52 (66.7%)	151 (68.3%)	0.763
Employment status, n (%)				
Employed (part-time or full-time)	92 (64.7%)	15 (29.5%)	96 (52.0%)	<0.001
Unemployed	19 (13.3%)	9 (11.5%)	28 (12.7%)	
Retired due to RRMS	10 (7.0%)	31 (39.7%)	41 (18.6%)	
Retired due to other reasons	4 (2.8%)	2 (2.6%)	6 (2.78%)	
Without paid employment	18 (12.6%)	13 (16.7%)	31 (14.0%)	
Some level of incapacity for work, n (%)	31 (21.7%)	44 (66.5%)	75 (34.9%)	<0.001
Time of MS evolution (years), mean (SD)	7.8 (6.5)	11.7 (6.9)	9.1 (6.9)	<0.001
Time with DMT treatment (years), mean (SD)	5.3 (4.1)	7.2 (4.7)	6.0 (4.4)	0.012
Time with current DMT treatment (years), mean (SD)	3.5 (3.7)	3.4 (3.3)	3.5 (3.5)	0.529
Use of previous DMT treatment, n (%)	75 (52.4%)	58 (74.4%)	133 (60.2%)	<0.001
Presence of relapses, n (%)				
Since diagnosis	125 (87.4%)	76 (97.4%)	201 (91.0%)	0.013
During the past 2 years	66 (46.2%)	34 (43.6%)	100 (45.2%)	0.714
During the past year	32 (22.4%)	20 (25.6%)	52 (23.5%)	0.585

DMT, disease-modifying therapy; EDSS, Expanded Disability Status Scale; MS, multiple sclerosis; RRMS, relapsing-remitting MS.

Table 4 Utility scores in patients with MS

	Utility (SD)	Importance (relative)	Importance (averaged)
Preventing relapse			
Presenting a relapse every 2 years	−0.367 (0.131)	8.3	10.4
Presenting a relapse every 5 years	0.367 (0.131)		
Preventing disease progression			
Preventing the disease from getting worse/progressing for 2 years	−0.445 (0.131)	10.0	11.1
Preventing the disease from getting worse/progressing for 5 years	0.445 (0.131)		
Side effect risk			
Rare but severe, life-threatening side effects	−1.457 (0.131)	32.9	26.5
Frequent but mild/moderate side effects	1.457 (0.131)		
Route of administration			
Oral	1.345 (0.195)	26.1	25.1
Subcutaneous–intramuscular	−0.381 (0.175)		
Intravenous	−0.965 (0.195)		
Frequency of administration			
Daily	−0.877 (0.206)	22.7	26.9
Every 2 days—weekly	−0.527 (0.251)		
Monthly	0.267 (0.206)		
Twice per year (Constant)	1.137 (0.251)		
	5.875 (0.133)		

MS, multiple sclerosis.

disability progression was the most important factor for treatment preferences.¹⁹ Risk of progressive multifocal leucoencephalopathy was the second most significant factor while the frequency of relapses had the least overall importance. Treatment frequency and route of administration showed a stronger influence on patient preferences compared with frequency of mild side effects in a German study.¹³ However, no efficacy attributes were assessed. Oral administration was preferred over injections by 93% of patients when treatment frequency and frequency of side effects were held constant.¹³ Poulos *et al*^{20, 21} performed studies in the USA and Germany assessing several attributes of injectable treatments using a discrete-choice approach to derive utilities: number of years until MS symptoms get worse, number of relapses in the next 4 years, injection time, frequency of injections, influenza-like symptoms and infection-site reactions. Both studies identified the number of years until MS symptoms get worse as being the most important attribute, followed by influenza-like symptoms, frequency of injections per month and number of relapses in the following years. A study performed by Wilson *et al*²² used different attributes (prevent progression, prevent relapse, prevent changes on MRI, improve symptoms, common and severe side effects, treatment administration and time on market) and established a ranking (0–10) approach to derive utilities. Prevention of disease progression, relapses and changes on MRI were assessed on an annual basis, but taking into account a maximum prevention period of 5 years, the most important attribute was the presence of severe side effects, followed by administration routes. In

addition, a study conducted in Canada, with a sample of 189 patients with RRMS as well as progressive MS using latent-class modelling, concluded that the most important attribute was the avoidance of serious adverse effects.²³

Our findings concur with those of Wilson *et al* using similar attributes to define scenarios and the same elicitation method. Prevention of relapse is not as relevant as preventing side effects.²² We identified main factors related to patient preferences for drug attributes, including previous experience with more than one DMT, number of relapses and HRQoL. Patients with prior DMT treatment gave higher importance to the impact of treatment on the prevention of relapse rate and lower importance to the side effects attribute. In a recent study performed to assess patient preferences for the full spectrum of DMT attributes, patients receiving their first DMT also gave higher importance to type, severity and duration of side effects.²⁴ On the other hand, patients who had previously received multiple DMTs gave higher importance to the effect on relapse rate and its severity. The fact that patients with a longer disease duration tend to prioritise the efficacy profile of DMTs may be indicative of a better understanding of the disease, both from a theoretical and from a practical point of view. Wilson *et al*¹⁴ identified that treatment-naïve patients had no significant relative preference for preventing disease progression, which could be associated with a lower disease activity. In addition, patients receiving the first-line DMTs such as β -interferons or glatiramer acetate displayed more aversion to fatal risk than those receiving the high-efficacy

Figure 1 Utility scores for each level of the attribute according to the EDSS score. EDSS, Expanded Disability Status Scale.

DMTs fingolimod or natalizumab. The ability of natalizumab-treated patients to assume therapy-associated risks and the factors involved in such risk acceptance was assessed in a study published by Tur *et al.*²⁸ The authors defined risk acceptance as a multifactorial phenomenon which is partly explained by an adaptive process involving the perception of MS as a more severe disease. Therefore, it would be important to give special attention to patients newly diagnosed in efficacy aspects of available therapies.

Our study has several limitations. First, the sample population included a high percentage of patients receiving their first DMT (39.8%). According to the study results, patients without prior treatment experience had a higher awareness about side effects, reducing the importance assigned to efficacy parameters. This high percentage of patients may explain the higher importance obtained for safety risk. Second, preference studies are classically limited in that the preference weights elicited are specific to the attributes and levels that are presented. It is possible that some attributes that are important to some patients were not included. In addition, the method used to derive utilities is a second

study limitation as utility values and importance derived from conjoint analysis depend on attributes and levels used to define scenarios. Treatment efficacy was assessed in terms of prevention of relapses and disease progression, but not in terms of improving MS symptoms. Previous studies that included both attributes derived a higher importance for the MS symptoms attribute than for the number of relapses.^{20, 21} On the other hand, side effect risk was defined in terms of severe and life-threatening adverse events, which could increase the importance assigned to this attribute. However, results obtained by Wilson *et al.*²² using a similar definition for the side effects attribute are aligned with our study. In addition, it is important to consider the number of levels included in each attribute. A higher number of levels tend to be related to higher importance assigned to the attribute, given that a higher variability in response options tends to occur. Finally, another potential limitation is the absence of additional patient factors or characteristics that may impact preferences, such as personality traits. For example, a neurotic personality profile has previously been predicted to have a higher acceptance of natalizumab-associated risks.²⁸

Table 5 Sociodemographic and clinical characteristics and individual importance assigned to each DMT attribute*

Sociodemographic or clinical characteristics	Preventing relapse	Preventing disease progression	Side effect risk	Route of administration
Previous DMT treatment				
No	9.0 (10.5)			21.8 (13.2)
Yes	11.3 (10.8)			27.3 (16.0)
p Value	0.027			0.008
Incapacity for work				
Partial incapacity		12.1 (7.5)		
Total incapacity		17.5 (12.8)		
Absolute incapacity		11.8 (7.9)		
Incapacity for severe disability		4.6 (4.8)		
Not recognised		9.6 (6.5)		
No incapacity		10.7 (10.2)		
p Value		0.048		
Anxiety/depression (EQ-5D)				
No		12.3 (10.1)		
Yes		9.6 (8.5)		
p Value		0.025		
Longer time since MS diagnosis (years)				
<1			39.0 (14.4)	
1–2			17.1 (14.7)	
2–5			24.0 (16.0)	
5–10			25.9 (16.7)	
10–20			30.3 (15.7)	
>20			21.8 (15.7)	
p Value			0.001	
Greater number of relapses in the past 2 years				
No relapses			28.4 (15.6)	23.8 (14.0)
1 relapse			27.6 (16.7)	23.9 (15.7)
2 or more relapses			18.3 (16.6)	31.1 (16.7)
p Value			0.005	0.030

*Only statistically significant results are included (p<0.05).

DMT, disease-modifying therapy; EQ-5D, EuroQol five dimensions questionnaire; MS, multiple sclerosis.

Despite these limitations, the study also has several strengths. The sample of 221 patients was managed in 17 different MS units at the national level, which allows results to be generalised to community practice. In addition, the sample size was large enough to allow the derivation of preference values according to the degree of disability (EDSS). Finally, a comprehensive battery of the most important DMT attributes, including efficacy, tolerability safety and convenience (route and frequency of administration), was analysed.

Patient preferences for DMT in our study were mainly driven by risk minimisation, route of administration and treatment schedule. There is no evidence that decisions based on patient preferences are better than those based on a drug's efficacy in order to achieve the best possible mid-long-term outcome for the patient. Nevertheless, understanding which DMT characteristics are meaningful to patients may help to tailor information and support decision-making in clinical practice.

Shared decision-making is a cornerstone of patient-centred care. A rating-based conjoint analysis is a feasible method for quantifying the relative preferences of patients with MS. Treatment decisions in MS should be made in collaboration between the neurologist and the

patient, and they should be based on the best available evidence as well as on patient values and preferences.^{29 30}

Author affiliations

¹Department of Neurology, Hospital Universitario Quirónsalud, Madrid, Spain

²Department of Neurology, Hospital General Universitario de Alicante, Alicante, Spain

³Health Economics and Outcomes Research Unit, Roche Farma SA, Madrid, Spain

⁴Medical Department, Roche Farma SA, Madrid, Spain

⁵Health Economics and Outcomes Research, IMS Health, Barcelona, Spain

Acknowledgements The authors acknowledge the other participating experts of the EMPOWER study. They also would like to express their gratitude to Cristina Garcia Bernaldez for leading the operational aspects of the study.

Contributors RA and JM developed the research question, designed the study and wrote the protocol. MR and AC performed the statistical analyses. All authors contributed to and have approved the final manuscript.

Funding The study was funded by Roche Farma SA, Spain.

Competing interests ER-B, DP and JM are employees of Roche Farma SA. MR and AC are employees of IMS Health.

Patient consent Obtained.

Ethics approval The study was approved by the Institutional Review Board of the Hospital Universitari Dr. Josep Trueta (Girona, Spain).

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement No additional data are available.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

REFERENCES

1. Compston A, Coles A. Multiple sclerosis. *Lancet* 2008;372:1502–17.
2. Torkildsen Ø, Myhr KM, Bo L. Disease-modifying treatments for multiple sclerosis—a review of approved medications. *Eur J Neurol* 2016;23(Suppl 1):18–27.
3. Sempere AP, Gimenez-Martinez J. Safety considerations when choosing the appropriate treatment for patients with multiple sclerosis. *Expert Op Drug Saf* 2014;13:1287–9.
4. Wingerchuk DM, Weinsheker BG. Disease modifying therapies for relapsing multiple sclerosis. *BMJ* 2016;354:i3518.
5. Brück W, Gold R, Lund BT, et al. Therapeutic decisions in multiple sclerosis: moving beyond efficacy. *JAMA Neurol* 2013;70:1315–24.
6. Heesen C, Solari A, Giordano A, et al. Decisions on multiple sclerosis immunotherapy: new treatment complexities urge patient engagement. *J Neurol Sci* 2011;306:192–7.
7. Colligan E, Metzler A, Tiryaki E. Shared decision-making in multiple sclerosis: a review. *Mult Scler* 2017;23:185–90.
8. Bruce JM, Lynch SG. Multiple sclerosis: MS treatment adherence—how to keep patients on medication? *Nat Rev Neurol* 2011;7:421–2.
9. Ryan M, Scott DA, Reeves C, et al. Eliciting public preferences for healthcare: a systematic review of techniques. *Health Technol Assess* 2001;5:1–186.
10. Bridges JF, Huber AB, Marshall D, et al. Conjoint analysis applications in health: a checklist of the ISPOR good research practices for conjoint analysis task force. *Value Health* 2011;14:403–13.
11. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. *Ann Neurol* 2011;69:292–302.
12. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). *Neurology* 1983;33:1444–52.
13. Utz JS, Hoog J, Wentrup A, et al. Patient preferences for disease-modifying drugs in multiple sclerosis therapy: a choice-based conjoint analysis. *Ther Adv Neurol Disord* 2014;7:263–75.
14. Wilson L, Loucks A, Bui C, et al. Patient-centered decision making: use of conjoint analysis to determine risk-benefit trade-offs for preference sensitive treatment choices. *J Neurol Sci* 2014;344:80–7.
15. Badia X, Roset M, Monserrat S, et al. The Spanish version of EuroQoL: a description and its applications. *Med Clin (Barcelona)* 1999;112(Suppl 1):79–85.
16. De las Cuevas C, Perestelo-Perez L, Rivero-Santana A, et al. Validation of the Spanish version of the 9-item Shared Decision-Making Questionnaire. *Health Expect* 2015;18:2143–53.
17. Yaras A, White MK, Björner JB. The development and validation of a revised version of the Medical Outcomes Study Cognitive Functioning Scale (Mos-Cog-R). *Value Health* 2013;16:334.
18. Ng P, Murray S, Hayes SM. Clinical decision-making in multiple sclerosis: challenges reported internationally with emerging treatment complexity. *Mult Scler Relat Disord* 2015;4:320–8.
19. Johnson FR, Van Houtven G, Ozdemir S, et al. Multiple sclerosis patients' benefit-risk preferences: serious adverse events risks versus treatment efficacy. *J Neurol* 2009;256:554–62.
20. Poulos C, Kinter E, Yang JC, et al. Patient preferences for injectable treatments for multiple sclerosis in the United States: a discrete-choice experiment. *Patient* 2016;9:171–80.
21. Poulos C, Kinter E, Yang JC, et al. A discrete-choice experiment to determine patient preferences for injectable multiple sclerosis treatments in Germany. *Ther Adv Neurol Disord* 2016;9:95–104.
22. Wilson LS, Loucks A, Gipson G, et al. Patient preferences for attributes of multiple sclerosis disease-modifying therapies development and results of a ratings-based conjoint analysis. *Int J MS Care* 2015;17:74–82.
23. Lynd LD, Traboulsee A, Marra CA, et al. Quantitative analysis of multiple sclerosis patients' preferences for drug treatments: a best-worst scaling study. *Ther Adv Neurol Disord* 2016;9:287–96.
24. Kremer IE, Evers SM, Jongen PJ, et al. Preferences of patients with multiple sclerosis for attributes of disease modifying drugs: a nominal group technique and best-worst scaling. *Value Health* 2015;18:A761.
25. D'Amico E, Leone C, et al. Disability may influence patient willingness to participate in decision making on first-line therapy in multiple sclerosis. *Funct Neurol* 2016;31:21–3.
26. Visser LH, Heerings MA, Jongen PJ, et al. Perspectives and experiences of Dutch multiple sclerosis patients and multiple sclerosis-specialized neurologists on injectable disease-modifying treatment. *Patient Prefer Adherence* 2016;10:659–67.
27. Garcia-Dominguez JM, Muñoz D, Comellas M, et al. Patient preferences for treatment of multiple sclerosis with disease-modifying therapies: a discrete choice experiment. *Patient Prefer Adherence* 2016;10:1945–56.
28. Tur C, Tintoré M, Vidal-Jordana A, et al. Risk acceptance in multiple sclerosis patients on natalizumab treatment. *PLoS ONE* 2013;8:e82796.
29. Gafson A, Craner MJ, Matthews PM. Personalised medicine for multiple sclerosis care. *Mult Scler* 2016. Published Online First 26 Sep 2016.
30. Fried TR. Shared decision making—finding the sweet spot. *N Engl J Med* 2016;374:104–6.